Skip to main content
Premium Trial:

Request an Annual Quote

RareCyte: David Kabakoff, Andy Schwab

In conjunction with RareCyte's recent financing round, David Kabakoff and Andy Schwab have joined the company's board of directors. Kabakoff is a partner at HealthQuest Capital and Schwab is a managing partner at 5AM Ventures. Both companies are RareCyte investors.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.